Article
An <i>in vitro</i> experimental pipeline to characterize the binding specificity of SARS-CoV-2 neutralizing antibodies
2023-04-21
Abstract excerpt
The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) has led to over 760 million cases and >6.8 million deaths worldwide. We developed a panel of human neutralizing monoclonal antibodies (mAbs) targeting the SARS-CoV-2 Spike protein using Harbour H2L2 transgenic mice immunized with Spike receptor binding domain (RBD) (1). Representative antibod...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 2682bd41-80ef-5974-884a-f09dca0e7e53
- DOI
- 10.1101/2023.04.20.537738
